CUV Share Price

Open 7.10 Change Price %
High 7.10 1 Day 0.00 0.00
Low 6.95 1 Week 0.00 0.00
Close 6.99 1 Month 0.19 2.79
Volume 12821 1 Year -1.28 -15.48
52 Week High 8.36
52 Week Low 5.91
CUV Important Levels
Resistance 2 7.13
Resistance 1 7.07
Pivot 7.01
Support 1 6.91
Support 2 6.85
ASX Australia Most Active Stocks
COE 0.30 3.45%
COE 0.30 3.45%
GPP 0.02 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
XST 0.02 100.00%
XST 0.02 100.00%
ATP 0.03 50.00%
ATP 0.03 50.00%
PMQ 0.03 50.00%
RMI 0.03 50.00%
RMI 0.03 50.00%
BNV 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
GDY 0.01 -50.00%
More..

Clinuvel Pharmaceuticals Ltd (ASX: CUV)

CUV Technical Analysis 3
As on 1st Nov 2017 CUV Share Price closed @ 6.99 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.94 & Buy for SHORT-TERM with Stoploss of 6.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
CUV Target for November
1st Target up-side 7.43
2nd Target up-side 7.73
3rd Target up-side 8.04
1st Target down-side 6.55
2nd Target down-side 6.25
3rd Target down-side 5.94
CUV Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.clinuvel.com
CUV Address
CUV
190 Queen Street
Level 14
Melbourne, VIC 3000
Australia
Phone: 61 3 9660 4900
Fax: 61 3 9660 4999
CUV Latest News
Interactive Technical Analysis Chart Clinuvel Pharmaceuticals Ltd ( CUV ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Clinuvel Pharmaceuticals Ltd
CUV Business Profile
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of skin disorders in Australia. Its lead drug compound is SCENESSE, a photoprotective drug for the treatment of erythropoietic protoporphyria, which has completed Phase II and III trials. The SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation and sunlight. It is also involved in the research of CUV9900, an alpha-melanocyte stimulating hormone (alpha-MSH) analogue. The company is headquartered in Melbourne, Australia.